Business, energy, technology, markets and global industry news from Business News Today

Polpharma Biologics

PharmaDeviceNews Polpharma Biologics
Teva Pharmaceutical Industries and Polpharma Biologics are advancing PB018, a proposed Ocrevus biosimilar for multiple sclerosis, under a global licensing agreement covering major pharmaceutical markets. Representative image.
Pharma & Biotech

Teva wants a slice of Roche’s CHF 7bn Ocrevus franchise, but PB018 still has a long road ahead

Teva gains broad rights to PB018 as Polpharma Biologics advances an Ocrevus biosimilar into clinical development for multiple sclerosis.

Read More
Representative image: Biologic vial and infusion setup for multiple sclerosis care, highlighting Teva Pharmaceutical Industries’ Polpharma Biologics deal for a proposed ocrelizumab biosimilar.
Pharma & Biotech

Teva and Polpharma Biologics sign global ocrelizumab biosimilar licensing deal

Teva Pharmaceutical Industries Ltd. has secured exclusive global commercialization rights to Polpharma Biologics’ proposed biosimilar to Ocrevus ocrelizumab for multiple sclerosis, covering both intravenous and subcutaneous formulations upon regulatory approval. Polpharma Biologics will remain responsible for development and manufacturing, while Teva will handle regulatory submissions and commercialization across major markets including the United States, Europe,

Read More
Representative image of biosimilar development and biologics manufacturing for autoimmune disease treatment, highlighting the Polpharma Biologics and Tuteur licensing deal to expand affordable therapy access across Latin America.
Pharma & Biotech

Can Polpharma Biologics and Tuteur improve access to autoimmune disease biologics in Latin America?

LATAM autoimmune care needs cheaper biologics. Polpharma Biologics and Tuteur are betting a biosimilar deal can shift access.

Read More